VRNA - Verona Pharma enters upto $400M debt facility
2024-01-02 04:56:29 ET
More on Verona Pharma
- Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment
- Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript
- Verona Pharma GAAP EPS of -$0.02 beats by $0.14
- Seeking Alpha’s Quant Rating on Verona Pharma
- Historical earnings data for Verona Pharma
For further details see:
Verona Pharma enters upto $400M debt facility